Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Recently Diagnosed Stage 3 Type 1 Diabetes

Posted by GlobeNewswire on June 13, 2026

-------- Original Version -----------

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

-------- English Version ------------

Press Release: Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes

-------- Link if available ----------

No Link available